clinical trial · NCT02455622
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Shire·phase4·completed·n = 21
Hunter SyndromeElaprase for intravenous (IV) infusion
brief summary
This long-term study will provide Elaprase treatment to children enrolled in this study and will utilize data from both enrolled patients and Hunter Outcome Survey (HOS) patient registry data to conduct the primary growth analysis to assess changes in height and weight in patients with Mucopolysaccharidosis II (Hunter syndrome) MPS II.
started
Oct 28, 2015
primary completion
Jul 29, 2025
completion
Jul 29, 2025
last updated
Apr 2, 2026
official title
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol